These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 37500964)

  • 21. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.
    Kim YY; Park MS; Aljoqiman KS; Choi JY; Kim MJ
    Clin Mol Hepatol; 2019 Sep; 25(3):223-233. PubMed ID: 30661336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma using imaging features of gadoxetic acid-enhanced magnetic resonance imaging.
    Byun J; Kim SY; Kim JH; Kim MJ; Yoo C; Shim JH; Lee SS
    Acta Radiol; 2021 Dec; 62(12):1548-1558. PubMed ID: 33197329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.
    Tan CH; Chou SC; Inmutto N; Ma K; Sheng R; Shi Y; Zhou Z; Yamada A; Tateishi R
    Korean J Radiol; 2022 Jul; 23(7):697-719. PubMed ID: 35555884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiomics model based on preoperative gadoxetic acid-enhanced MRI for predicting liver failure.
    Zhu WS; Shi SY; Yang ZH; Song C; Shen J
    World J Gastroenterol; 2020 Mar; 26(11):1208-1220. PubMed ID: 32231424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced multi-detector computed tomography in detecting hepatocellular carcinoma: a meta-analysis of eight prospective studies.
    Li J; Wang J; Lei L; Yuan G; He S
    Eur Radiol; 2019 Dec; 29(12):6519-6528. PubMed ID: 31250172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional liver function analysis with gadoxetic acid-enhanced MRI and virtual hepatectomy: prediction of postoperative short-term outcomes for HCC.
    Huang M; Shen S; Cai H; Peng Z; Chiu WHK; Li ZP; Peng B; Feng ST
    Eur Radiol; 2021 Jul; 31(7):4720-4730. PubMed ID: 33449173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The usefulness of gadoxetic acid-enhanced dynamic magnetic resonance imaging in hepatocellular carcinoma: toward improved staging.
    Choi SH; Byun JH; Kwon HJ; Ha HI; Lee SJ; Kim SY; Won HJ; Kim PN
    Ann Surg Oncol; 2015 Mar; 22(3):819-25. PubMed ID: 25201507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adding ancillary features to enhancement patterns of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging improves diagnostic performance.
    Min JH; Kim YK; Sinn DH; Choi SY; Jeong WK; Lee WJ; Ha SY; Ahn S; Kim MJ
    Abdom Radiol (NY); 2018 Sep; 43(9):2309-2320. PubMed ID: 29470629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
    Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
    Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
    Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
    Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
    Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
    Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of MRI with hepatospecific contrast agent in the identification and characterization of focal liver lesions: pathological correlation in explanted livers.
    Orlacchio A; Chegai F; Fabiano S; Merolla S; Funel V; Di Giuliano F; Manuelli M; Tisone G; Francioso S; Angelico M; Palmieri G; Simonetti G
    Radiol Med; 2016 Jul; 121(7):588-96. PubMed ID: 27100719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC.
    Park CJ; An C; Park S; Choi JY; Kim MJ
    Eur Radiol; 2018 Apr; 28(4):1476-1484. PubMed ID: 29063251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computer-aided hepatocellular carcinoma detection on the hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging using a convolutional neural network: Feasibility evaluation with multi-sequence data.
    Cho Y; Han YE; Kim MJ; Park BJ; Sim KC; Sung DJ; Han NY; Park YS
    Comput Methods Programs Biomed; 2022 Oct; 225():107032. PubMed ID: 35930863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background.
    Kitao A; Matsui O; Yoneda N; Kozaka K; Kobayashi S; Koda W; Inoue D; Ogi T; Yoshida K; Gabata T
    Eur Radiol; 2020 Jun; 30(6):3438-3447. PubMed ID: 32064560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
    Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
    Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Gadoxetic Acid-enhanced Liver MRI and Mortality in More than 30 000 Patients with Hepatocellular Carcinoma: A Nationwide Analysis.
    Kang TW; Kong SY; Kang D; Kang MW; Kim YK; Kim SH; Sinn DH; Kim YA; Choi KS; Lee ES; Woo SM; Back JH; Guallar E; Cho J
    Radiology; 2020 Apr; 295(1):114-124. PubMed ID: 32013789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.